Our experimental validation of FOXP3 knockdown effects was restricted to two ccRCC cell lines (Caki-1 and 769-P), limiting the representation of ccRCC tumor heterogeneity; future studies should incorporate additional cell lines and in vivo models for comprehensive validation. Here, FOXP3 is linked to nonpapillary renal cell carcinoma.